Better Buy: Pfizer vs. Bristol-Myers Squibb
A lot is changing for two of the biggest drugmakers on the planet. Pfizer (NYSE: PFE) is merging its Upjohn business with Mylan (NASDAQ: MYL). Bristol-Myers Squibb (NYSE: BMY) just completed its acquisition of Celgene.
Investors have rewarded Bristol-Myers Squibb's moves more so far this year than they have Pfizer's. But which of these two big pharmaceutical stocks is the better pick? Here's how BMS and Pfizer stack up against each other on several key fronts.
Image source: Getty Images.
Source Fool.com
